Clinical trials: Nonproliferative Diabetic Retinopathy
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner
Retinopathy, Diabetic
Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
The purpose of this study is to specifically assess the effect of intravitreal aflibercept injections on the health of cells and the flow of blood through the retinal blood vessels by using advanced technology called adaptive…
- Trial name
- PRAVA (NCT04702048)
- Testing
- Aflibercept Injection
- Where
- United States
- Sponsor
- University of Rochester
Severe Nonproliferative, Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Diabetic Retinopathy
Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic…
- Conditions
- Severe Nonproliferative, Proliferative Diabetic Retinopathy, Active Photocoagulated Diabetic Retinopathy
- Trial name
- NCT00600262
- Testing
- intravitreal bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Type 2 Diabetes Mellitus, Mild Nonproliferative Diabetic Retinopathy
Biomarkers of Diabetic Retinopathy Progression
The purpose of this study is to validate a predictive model of diabetic retinopathy progression in patients with diabetes mellitus type 2 patients to clinically significant macular edema (CSME) needing treatment either…
- Trial name
- C-Tracer (NCT01607190)
- Where
- 2 sites in India, Portugal
- Volunteers
- 200 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
The purpose of this study is explore if a partnership and screening program put in place between a busy retina practice and their referring diabetes care offices can improve diabetic retinopathy and diabetic macular edema…
- Conditions
- Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- DIVER (NCT01790945)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Diabetic Retinopathy
Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2
This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss.
- Trial name
- CPM (NCT00763802)
- Where
- Portugal
- Volunteers
- 400 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-Proliferative Diabetic Retinopathy
Safety and Efficacy of Faricimab in Patients With NPDR
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
- Trial name
- MAGIC (NCT05681884)
- Testing
- Faricimab
- Where
- 16 sites in United States
- Volunteers
- 179 people
- Sponsor
- Greater Houston Retina Research
NPDR - Non Proliferative Diabetic Retinopathy
Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2
Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional clinical Study with 2 years of…
- Trial name
- CORDIS (NCT03696810)
- Testing
- Laboratory tests
- Where
- Portugal
- Volunteers
- 141 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Diabetic Retinopathy
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina).
- Trial name
- NAAVIGATE (NCT07592273)
- Testing
- Surabgene Lomparvovec, Topical Steroid, Artificial Tears
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 576 people
- Sponsor
- AbbVie
Diabetic Retinopathy
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab…
- Trial name
- PAVILION (NCT04503551)
- Testing
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Moderate Non-proliferative Diabetic Retinopathy
The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy
The purpose of this study is to evaluate the role of alpha lipoic acid in patients who have moderate non-proliferative diabetic retinopathy.
- Trial name
- ALA-TPD (NCT01880372)
- Testing
- Alpha Lipoic Acid
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ferris State University
Diabetic Retinopathy
Evaluation of RC28-E Injection in Diabetic Retinopathy
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately…
- Trial name
- NCT04782128
- Testing
- RC28-E injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.